Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Psychemedics Corporation
PMDPsychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. The company's testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. It offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. The company was incorporated in 1986 and is headquartered in Dallas, Texas. Address: 5220 Spring Valley Road, Dallas, TX, United States, 75254
Analytics
Objectif de Cours de WallStreet
32 USDRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés PMD
Analyse des dividendes PMD
Croissance des dividendes sur 5 ans
-80 %Croissance continue
–Ratio de distribution Moyenne sur 5 ans
12 %Historique des dividendes PMD
Valorisation des titres PMD
financières PMD
Résultats | 2019 | Dynamique |